Factors associated with ethnical disparity in overall survival for patients with hepatocellular carcinoma

Juan Li1, Bettina E Hansen1, Maikel P Peppelenbosch1

  • 1Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.

Oncotarget
|January 26, 2017
PubMed

Insights

African Americans with hepatocellular carcinoma (HCC) face worse survival due to late diagnosis and limited treatment options. Addressing these disparities is crucial for improving outcomes in HCC patients.

Area of Science:

  • Hepatology
  • Oncology
  • Health Disparities Research

Background:

  • Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality globally.
  • Significant ethnic survival disparities exist for HCC patients in the United States.

Purpose of the Study:

  • To identify and evaluate the factors contributing to ethnic survival disparities in hepatocellular carcinoma (HCC) patients.
  • To compare overall survival rates across different ethnic groups diagnosed with HCC.

Main Methods:

  • Utilized the SEER database to identify 33,062 HCC patients diagnosed between 2004 and 2012.
  • Employed Kaplan-Meier curves and Cox proportional hazard models to analyze overall survival and contributing factors.
  • Stratified analysis included patients undergoing liver transplantation and those meeting Milan criteria.

Main Results:

  • African Americans exhibited worse survival (HR, 1.18) compared to Non-Hispanic Whites, while Asians had better survival (HR, 0.85).
  • Tumor presentation and treatment-related factors, particularly tumor size (HR, 1.11), significantly contributed to survival disparities.
  • No significant survival disparity was observed among patients undergoing liver transplantation, especially those within Milan criteria after adjustment.

Conclusions:

  • Poorer tumor presentation at diagnosis, limited benefits from surgical resection, and restricted access to liver transplantation contribute to worse survival for African Americans with HCC.
  • Targeted interventions addressing these factors are essential to reduce ethnic survival disparities in HCC.
  • Further research is needed to understand the superior survival observed in Asian HCC patients.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
245
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
807
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
305
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
677
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
691
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
320